Market Overview

UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb Following Global Pharma Review

Share:
Related BMY
UPDATE: USDA Approves Supplimental Biologics License
USDA Accepts Supplemental Biologics License Application for Yervoy As Adjuvant Treatment for Patients with Stage 3 Melanoma Who Are at High Risk of Recurrence
FDA accepts Bristol-Myers' application for expanded use of Yervoy (Seeking Alpha)

In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), but lowered the price target from $53.50 to $53.00.

In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”

Bristol-Myers Squibb Co. closed on Thursday at $46.17.

Latest Ratings for BMY

DateFirmActionFromTo
Feb 2015Argus ResearchMaintainsBuy
Feb 2015JefferiesMaintainsHold
Jan 2015BarclaysMaintainsEqual-weight

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: Jefferies Jeffrey HolfordAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

Around the Web, We're Loving...

Get Benzinga's Newsletters